Please select the option that best describes you:

If you’re transitioning laterally between biologic classes due to adverse effects, do you repeat the loading dose?  

For instance, if a patient develops conjunctivitis on IL 4/13 inhibitor (dupiliumab) to a IL13 (Adbry, Ebyglyss), or between IL13s? Similarly, this question pertains for 17s, and 23s. 



Answer from: at Academic Institution
Comments
at Precision Dermatology, P.A.
I think starting with a loading dose when switchin...
at Jefferson Regional Medical Center
I do loading dose also.
Sign in or Register to read more

Answer from: at Community Practice
Sign in or Register to read more

Answer from: at Academic Institution
Sign in or Register to read more